Literature DB >> 19648286

Golgi dysfunction is a common feature in idiopathic human pulmonary hypertension and vascular lesions in SHIV-nef-infected macaques.

Pravin B Sehgal1, Somshuvra Mukhopadhyay, Kirit Patel, Fang Xu, Sharilyn Almodóvar, Rubin M Tuder, Sonia C Flores.   

Abstract

Golgi dysfunction has been previously investigated as a mechanism involved in monocrotaline-induced pulmonary hypertension (PAH). In the present study, we addressed whether Golgi dysfunction might occur in pulmonary vascular cells in idiopathic PAH (IPAH) and whether there might be a causal relationship between trafficking dysfunction and vasculopathies of PAH. Quantitative immunostaining for the Golgi tethers giantin and p115 on human lung tissue from patients with IPAH (n = 6) compared with controls demonstrated a marked cytoplasmic dispersal of giantin- and p115-bearing vesicular elements in vascular cells in the proliferative, obliterative, and plexiform lesions in IPAH and an increase in the amounts of these Golgi tethers/matrix proteins per cell. The causality question was approached by genetic means using human immunodeficiency virus (HIV)-Nef, a protein that disrupts endocytic and trans-Golgi trafficking. Macaques infected with a chimeric simian immunodeficiency virus (SIV) containing the HIV-nef gene (SHIV-nef), but not the nonchimeric SIV virus containing the endogenous SIV-nef gene, displayed pulmonary arterial vasculopathies similar to those in human IPAH. Giantin and p115 levels and their subcellular distribution in pulmonary vascular cells in lungs of SHIV-nef infected macaques (n = 4) were compared with SIV-infected (n = 3) and an uninfected macaque control. Only macaques infected with chimeric SHIV-nef showed pulmonary vascular lesions containing cells with dramatic cytoplasmic dispersal and an increase in giantin and p115. Specifically, the HIV-Nef-positive cells showed increased giantin, p115, and the activated transcription factor PY-STAT3. These data represent the first test of the Golgi dysfunction hypothesis in IPAH and place trafficking and Golgi disruption in the chain of causality of pulmonary vasculopathies in the macaque model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19648286      PMCID: PMC2770782          DOI: 10.1152/ajplung.00087.2009

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  34 in total

1.  Sorting nexin 6, a novel SNX, interacts with the transforming growth factor-beta family of receptor serine-threonine kinases.

Authors:  W T Parks; D B Frank; C Huff; C Renfrew Haft; J Martin; X Meng; M P de Caestecker; J G McNally; A Reddi; S I Taylor; A B Roberts; T Wang; R J Lechleider
Journal:  J Biol Chem       Date:  2001-03-08       Impact factor: 5.157

Review 2.  The mechanisms of vesicle budding and fusion.

Authors:  Juan S Bonifacino; Benjamin S Glick
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

3.  Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension.

Authors:  K B Lane; R D Machado; M W Pauciulo; J R Thomson; J A Phillips; J E Loyd; W C Nichols; R C Trembath
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

4.  HIV-2 and SIV nef proteins target different Src family SH3 domains than does HIV-1 Nef because of a triple amino acid substitution.

Authors:  Y Collette; S Arold; C Picard; K Janvier; S Benichou; R Benarous; D Olive; C Dumas
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

5.  Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension.

Authors:  Nung Rudarakanchana; Julia A Flanagan; Hailan Chen; Paul D Upton; Rajiv Machado; D Patel; Richard C Trembath; Nicholas W Morrell
Journal:  Hum Mol Genet       Date:  2002-06-15       Impact factor: 6.150

6.  SIV/HIV Nef recombinant virus (SHIVnef) produces simian AIDS in rhesus macaques.

Authors:  C P Mandell; R A Reyes; K Cho; E T Sawai; A L Fang; K A Schmidt; P A Luciw
Journal:  Virology       Date:  1999-12-20       Impact factor: 3.616

Review 7.  Primary pulmonary hypertension.

Authors:  James R Runo; James E Loyd
Journal:  Lancet       Date:  2003-05-03       Impact factor: 79.321

8.  Signaling molecules in nonfamilial pulmonary hypertension.

Authors:  Lingling Du; Christopher C Sullivan; Danny Chu; Augustine J Cho; Masakuni Kido; Paul L Wolf; Jason X-J Yuan; Reena Deutsch; Stuart W Jamieson; Patricia A Thistlethwaite
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

9.  Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension.

Authors:  Ayako Nishihara; Tetsuro Watabe; Takeshi Imamura; Kohei Miyazono
Journal:  Mol Biol Cell       Date:  2002-09       Impact factor: 4.138

10.  Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells.

Authors:  Toshihiko Nishimura; Laszlo T Vaszar; John L Faul; Guohua Zhao; Gerald J Berry; Lingfang Shi; Daoming Qiu; Gail Benson; Ronald G Pearl; Peter N Kao
Journal:  Circulation       Date:  2003-09-08       Impact factor: 29.690

View more
  31 in total

1.  Injection drug use as a "second hit" in the pathogenesis of HIV-associated pulmonary hypertension.

Authors:  M Patricia George; Hunter C Champion; Mark T Gladwin; Karen A Norris; Alison Morris
Journal:  Am J Respir Crit Care Med       Date:  2012-06-01       Impact factor: 21.405

2.  The Golgi apparatus regulates cGMP-dependent protein kinase I compartmentation and proteolysis.

Authors:  Shin Kato; Jingsi Chen; Katherine H Cornog; Huili Zhang; Jesse D Roberts
Journal:  Am J Physiol Cell Physiol       Date:  2015-04-08       Impact factor: 4.249

3.  Pulmonary hypertension associated with HIV infection: pulmonary vascular disease: the global perspective.

Authors:  Sharilyn Almodovar; Stefania Cicalini; Nicola Petrosillo; Sonia C Flores
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

Review 4.  The complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS.

Authors:  Sharilyn Almodovar
Journal:  Viral Immunol       Date:  2014-05-05       Impact factor: 2.257

5.  Subcellular mechanisms in pulmonary arterial hypertension: combinatorial modalities that inhibit anterograde trafficking and cause bone morphogenetic protein receptor type 2 mislocalization.

Authors:  Yang-Ming Yang; Kirk B Lane; Pravin B Sehgal
Journal:  Pulm Circ       Date:  2013-12-04       Impact factor: 3.017

6.  Lung Vascular Remodeling, Cardiac Hypertrophy, and Inflammatory Cytokines in SHIVnef-Infected Macaques.

Authors:  Sharilyn Almodovar; Jessica Swanson; Luis D Giavedoni; Sreetharan Kanthaswamy; Carlin S Long; Norbert F Voelkel; Michael G Edwards; Joy M Folkvord; Elizabeth Connick; Susan V Westmoreland; Paul A Luciw; Sonia C Flores
Journal:  Viral Immunol       Date:  2017-12-19       Impact factor: 2.257

7.  Pathogenesis of HIV-associated pulmonary hypertension: potential role of HIV-1 Nef.

Authors:  Sharilyn Almodovar; Priscilla Y Hsue; Julie Morelli; Laurence Huang; Sonia C Flores
Journal:  Proc Am Thorac Soc       Date:  2011-06

8.  Human cartilage fragments in a composite scaffold for single-stage cartilage repair: an in vitro study of the chondrocyte migration and the influence of TGF-β1 and G-CSF.

Authors:  A Marmotti; D E Bonasia; M Bruzzone; R Rossi; F Castoldi; G Collo; C Realmuto; C Tarella; G M Peretti
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-11-10       Impact factor: 4.342

Review 9.  Pathogenesis of HIV and the lung.

Authors:  Matthew R Gingo; Alison Morris
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

10.  Hypothesis: Neuroendocrine Mechanisms (Hypothalamus-Growth Hormone-STAT5 Axis) Contribute to Sex Bias in Pulmonary Hypertension.

Authors:  Pravin B Sehgal; Yang-Ming Yang; Edmund J Miller
Journal:  Mol Med       Date:  2015-07-30       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.